Prognostic significance of immunohistochemical phenotypes in patients treated for high-grade cervical intraepithelial neoplasia

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Origoni, Massimo ^a   Parma, Marta ^a   Dell'Antonio, Giacomo ^a   Gelardi, Chiara ^a   Stefani, Chiara ^a   Salvatore, Stefano ^a   Candiani, Massimo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; T BOX TRANSCRIPTION FACTOR; T BOX TRANSCRIPTION FACTOR TBX21; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DENDRITIC CELL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OUTCOME ASSESSMENT; PHENOTYPE; RETROSPECTIVE STUDY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; YOUNG ADULT; CANCER GRADING; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; PAPILLOMA VIRUS; PATHOGENICITY; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE SYSTEM; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRIDAE; PHENOTYPE; PROGNOSIS; T-BOX DOMAIN PROTEINS;

EID: 84893344449     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/831907     Document Type: Article

References (48)

1. I. Soerjomataram, J. Lortet-Tieulent, D. M. Parkin et al., "Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions," The Lancet, vol. 380, no. 9856, pp. 1840-1850, 2012.
2. H. zur Hausen, "Papillomaviruses and cancer: from basic studies to clinical application," Nature Reviews Cancer, vol. 2, no. 5, pp. 342-350, 2002.
3. F. X. Bosch, M. M. Manos, N. Munoz et al., "Prevalence of human papillomavirus in cervical cancer: a worldwide perspective," Journal of the National Cancer Institute, vol. 87, no. 11, pp. 796-802, 1995.
4. M. Schiffman and N. Wentzensen, "Human Papillomavirus infection and the multistage carcinogenesis of cervical cancer," Cancer Epidemiology, Biomarkers & Prevention, vol. 22, no. 4, pp. 553-560, 2013.
5. M. Evander, K. Edlund, A. Gustafsson et al., "Human papillomavirus infection is transient in young women: a population-based cohort study," Journal of Infectious Diseases, vol. 171, no. 4, pp. 1026-1030, 1995.
6. G. Y. F. Ho, R. Bierman, L. Beardsley, C. J. Chang, and R. D. Burk, "Natural history of cervicovaginal papillomavirus infection in young women," The New England Journal of Medicine, vol. 338, no. 7, pp. 423-428, 1998. (Pubitemid 28135669)
7. M. Schiffman, P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder, "Human papillomavirus and cervical cancer," The Lancet, vol. 370, no. 9590, pp. 890-907, 2007.
8. R. W. Tindle, "Immune evasion in human papillomavirus-associated cervical cancer," Nature Reviews Cancer, vol. 2, no. 1, pp. 59-65, 2002.
9. M. H. Hibma, "The immune response to Papillomavirus during infection persistence and regression," The Open Virology Journal, vol. 6, supplement 2, pp. 241-248, 2012.
10. T. Sasagawa, H. Takagi S, and S. Makinoda, "Immune responses against Human Papillomavirus (HPV) infection and evasion of host defense on cervical cancer," Journal of Infection and Chemotherapy, vol. 18, no. 6, pp. 807-815, 2012.
11. K. U. Petry, D. Scheffel, U. Bode et al., "Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions," International Journal of Cancer, vol. 57, no. 6, pp. 836-840, 1994. (Pubitemid 24216820)
12. D. Serraino, P. Carrieri, C. Pradier et al., "Risk of invasive cervical cancer among women with, or at risk for, HIV infection," International Journal of Cancer, vol. 82, no. 3, pp. 334-337, 1999. (Pubitemid 29302973)
13. M. I. Alloub, B. B. B. Barr, K. M. McLaren, I. W. Smith, W. H. Bunney, and G. E. Smart, "Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts," British Medical Journal, vol. 298, no. 6667, pp. 153-156, 1989.
14. F. B. Lillo, D. Ferrari, F. Veglia et al., "Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy," Journal of Infectious Diseases, vol. 184, no. 5, pp. 547-551, 2001. (Pubitemid 32783544)
15. C. Uberti-Foppa, M. Origoni, M. Maillard et al., "Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women," Journal of Medical Virology, vol. 56, no. 2, pp. 133-137, 1998. (Pubitemid 28419274)
16. C. K. Fairley, S. Chen, S. N. Tabrizi et al., "Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment," Nephrology Dialysis Transplantation, vol. 9, no. 4, pp. 416-420, 1994. (Pubitemid 24136276)
17. A. Carus, M. Ladekarl, B. S. Nedergaard, and F. Donskov, "Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localized cervical cancer," British Journal of Cancer, vol. 108, pp. 2116-2122, 2013.
18. P. J. de Vos van Steenwijk, T. H. Ramwadhdoebe, R. Goedemans et al., "Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma," International Journal of Cancer, vol. 133, no. 12, pp. 2884-2894, 2013.
19. S. J. Piersma, E. S. Jordanova, M. I. E. van Poelgeest et al., "High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer," Cancer Research, vol. 67, no. 1, pp. 354-361, 2007.
20. J. Konya and J. Dillner, "Immunity to oncogenic human papillomaviruses," Advances in Cancer Research, vol. 82, pp. 205-238, 2001.
21. M. Evans, L. K. Borysiewicz, A. S. Evans et al., "Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6," Journal of Immunology, vol. 167, no. 9, pp. 5420-5428, 2001. (Pubitemid 33009783)
22. S. L. Giannini, P. Hubert, J. Doyen, J. Boniver, and P. Delvenne, "Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix," International Journal of Cancer, vol. 97, no. 5, pp. 654-659, 2002. (Pubitemid 34087806)
23. A. Manickam, M. Sivanandham, and I. L. Tourkova, "Immunological role of dendritic cells in cervical cancer," Advances in Experimental Medicine and Biology, vol. 601, pp. 155-162, 2007.
24. S.-J. Um, J.-W. Rhyu, E.-J. Kim, K.-C. Jeon, E.-S. Hwang, and J.-S. Park, "Abrogation of IRF-1 response by high-risk HPV E7 protein invivo," Cancer Letters, vol. 179, no. 2,pp. 205-212, 2002. (Pubitemid 34215112)
25. S. Monnier-Benoit, F. Mauny, D. Riethmuller et al., " Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix," Gynecologic Oncology, vol. 102, no. 1, pp. 22-31, 2006. (Pubitemid 44183744)
26. H. J. Bontkes, T. D. de Gruijl, and A. I. C. van der Muysemberg, "Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia," International Journal of Cancer, vol. 88, no. 1, pp. 92-98, 2000.
27. A. de Jong, S. H. van der Burg, K. M. C. Kwappenberg et al., "Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects," Cancer Research, vol. 62, no. 2, pp. 472-479, 2002.
28. N. Coleman, H. D. L. Birley, A. M. Renton et al., "Immunological events in regressing genital warts," American Journal of Clinical Pathology, vol. 102, no. 6, pp. 768-774, 1994.
29. K. Hong, C. E. Greer, N. Ketter, G. van Nest, and X. Paliard, "Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts," Journal of Virology, vol. 71, no. 9, pp. 6427-6432, 1997. (Pubitemid 27355296)
30. M. Origoni, P. Cristoforoni, S. Costa, L. Mariani, P. Scirpa, and A. Lorincz M, "HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice," Ecancermedicalscience, vol. 6, article 258, 2012.
31. L. Mariani, M. Sideri, S. Costa, P. Cristoforoni, M. Origoni, and M. Preti, "Human papillomavirus DNA and Pap tests: the need for cotesting in opportunistic setting during the transition time," Journal of Lower Genital Tract Disease, vol. 17, no. 3, pp. 362-365, 2013.
32. M. Origoni, G. Carminati, S. Rolla et al., "Human papillomavirus viral load expressed as Relative Light Units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in Atypical Squamous Cells of Undetermined Significance (ASCUS) cytology," European Journal of Clinical Microbiology and Infectious Diseases, vol. 31, no. 9, pp. 2401-2406, 2012.
33. M. Origoni, G. Carminati, M. Sideri, M. Clementi, S. Rolla, and M. Candiani, "'Low-grade positivity' of HPV viral load after Atypical Squamous Cells of Undetermined Significance (ASC-US) cytology identifies women at low-risk for cervical intraepithelial neoplasia grade 2 and 3," European Journal of Gynaecological Oncology, vol. 33, no. 3, pp. 261-264, 2012.
34. M. Origoni, "High viral load identifies cervical lesions - letter," Cancer Epidemiology Biomarkers & Prevention, vol. 22, no. 10, article 1924, 2013.
35. J. M. M. Walboomers, M. V. Jacobs, M. M. Manos et al., "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide," Journal of Pathology, vol. 189, pp. 12-19, 1999. (Pubitemid 29406813)
36. A.-B. Moscicki, M. Schiffman, S. Kjaer, and L. L. Villa, "Chapter 5: updating the natural history of HPV and anogenital cancer," Vaccine, vol. 24, no. 3, pp. S42-S51, 2006. (Pubitemid 44308674)
37. D. M. Parkin and F. Bray, "Chapter 2: the burden of HPV-related cancers," Vaccine, vol. 24, no. 3, pp. S11-S25, 2006.
38. M. Y. Tjiong, T. A. Out, J. Ter Schegget, M. P. M. Burger, and N. Van der Vange, "Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review," International Journal of Gynecological Cancer, vol. 11, no. 1, pp. 9-17, 2001.
39. A. Ferenczy, F. Coutlée, E. Franco, and C. Hankins, "Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments," Canadian Medical Association Journal, vol. 169, no. 5, pp. 431-434, 2003. (Pubitemid 37076256)
40. M. Origoni, C. Stefani, G. Dell'Antonio, G. Carminati, M. Parma, and M. Candiani, "Cervical human Papillomavirus in transplanted Italian women: a long-term prospective follow-up study," Journal of Clinical Virology, vol. 51, no. 4, pp. 250-254, 2011.
41. D. H. Schuurhuis, N. Fu, F. Ossendorp, and C. J. M. Melief, "Ins and outs of dendritic cells," International Archives of Allergy and Immunology, vol. 140, no. 1, pp. 53-72, 2006.
42. J. Banchereau, F. Briere, C. Caux et al., "Immunobiology of dendritic cells," Annual Review of Immunology, vol. 18, pp. 767-811, 2000.
43. S. C. Fausch, D. M. Da Silva, M. P. Rudolf, and W. M. Kast, "Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses," Journal of Immunology, vol. 169, no. 6, pp. 3242-3249, 2002.
44. I. C. Le Poole, W. M. ElMasri, C. J. Denman et al., "Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells," Cancer Immunology, Immunotherapy, vol. 57, no. 6, pp. 789-797, 2008.
45. A. de Jong, M. I. E. van Poelgeest, J. M. Van der Hulst et al., "Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6," Cancer Research, vol. 64, no. 15, pp. 5449-5455, 2004.
46. D. E. Warrino, W. C. Olson, W. T. Knapp et al., "Disease-stage variance in functional CD4+ T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes," Clinical Cancer Research, vol. 10, no. 10, pp. 3301-3308, 2004.
47. S. Seresini, M. Origoni, F. Lillo et al., "IFN-γ produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions," Journal of Immunology, vol. 179, no. 10, pp. 7176-7183, 2007.
48. R. D. M. Steenbergen, V. E. OudeEngberink, D. Kramer et al., "Down-regulation of GATA-3 expression during human papillomavirus-mediated immortalization and cervical carcinogenesis," American Journal of Pathology, vol. 160, no. 6, pp. 1945-1951, 2002.